Prospective, randomized trial of rapamycin [sirolimus]- and zotarolimus-eluting stents for the reduction of coronary restenosis.

Trial Profile

Prospective, randomized trial of rapamycin [sirolimus]- and zotarolimus-eluting stents for the reduction of coronary restenosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Probucol (Primary) ; Sirolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms ISAR-TEST-5
  • Most Recent Events

    • 04 Jan 2012 Actual end date Sep 2010 added as reported by ClinicalTrials.gov.
    • 21 Sep 2010 Primary endpoint 'cardiac death, target vessel-related myocardial infarction and target lesion revascularisation composite' has been met, according to results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 21 Sep 2010 Status changed from active, no longer recruiting to completed, based on results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top